Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
Company overview
Financial review
Conclusions
Novartis pipeline in Phase 3
Oncology
AAA617
Code Name
Solid tumors
PluvictoⓇ
Mechanism
INNOVATION
8 lead indications
Lead indication
CGRPR antagonist
S1P1,5 receptor modulator
BTK inhibitor
Indication(s)
Migraine, pediatrics
Multiple sclerosis, pediatrics
Multiple sclerosis
SMN1 gene replacement therapy SMA IT administration
CD20 Antagonist
Multiple sclerosis, pediatrics
Indication(s)
Radioligand therapy target PSMA Metastatic castration-resistant prostate cancer (mCRPC),
pre-taxane
Metastatic hormone sensitive prostate cancer (mHSPC)
Oligometastatic prostate cancer
Radioligand therapy target SSTR Gastroenteropancreatic neuroendocrine tumors, 1st line in G2/3
PI3K-alpha inhibitor
KRAS inhibitor
tumors (GEP-NET 1L G3)
Lymphatic malformations
2/3L Non-small cell lung cancer
Neuroscience
Code Name
AMG334 AimovigⓇ
BAF312 MayzentⓇ
LOU064 remibrutinib
OAV101 AVXS-101
OMB157 KesimptaⓇ
Immunology
Mechanism
Code Name
AIN457 CosentyxⓇ
Mechanism
IL17A inhibitor
LOU064 remibrutinib
BTK inhibitor
Atypical hemolytic uraemic syndrome
1L Immune Thrombocytopenia
2L Immune Thrombocytopenia
QGE031 ligelizumab
VAY736 ianalumab
IgE inhibitor
warm Autoimmune Hemolytic Anemia
BAFF-R inhibitor, ADCC-
mediated B-cell depletor
Indication(s)
Giant cell arteritis
Polymyalgia rheumatica
Rotator cuff tendinopathy
Chronic spontaneous urticaria
Chronic spontaneous urticaria, pediatrics
CINDU
Food allergy
Sjögren's
Lupus Nephritis
Systemic lupus erythematosus
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
Abbreviations
References
AAA6011 LutatheraⓇ
BYL719 PiqrayⓇ, Vijoyce®
JDQ443 opnurasib
Hematology
ABL001 ScemblixⓇ®
ETB115 PromactaⓇ
LNP023 iptacopan
VAY736 ianalumab
BCR-ABL inhibitor
Thrombopoietin receptor
(TPO-R) agonist
CFB inhibitor
BAFF-R inhibitor, ADCC-
mediated B-cell depletor
Chronic myeloid leukemia, 1st line
Radiation sickness syndrome
Cardiovascular, Renal and Metabolic
Code
Name
EXV811 atrasentan
FUB523 zigakibart
KJX839 Leqvio®
Mechanism
ETA receptor antagonist
Anti-APRIL
siRNA (regulation of LDL-C)
LNP023 iptacopan
CFB inhibitor
Indication(s)
IgA nephropathy
IgA nephropathy
CVRR-LDLC
Primary prevention
Hyperlipidemia, pediatrics
IgA nephropathy
TQJ230 pelacarsen
1. 177 Lu-dotatate in US.
C3 glomerulopathy
C3 glomerulopathy, pediatrics
IC-MPGN
Others
Code
Name
Mechanism
IB&GH
Indication(s)
COA566 Coartem®
KLU156 Ganaplacide +
lumefantrine
QMF149 AtecturaⓇ
Others
PGH-1 (artemisinin
combination therapy)
Non-artemisinin plasmodium
falciparum inhibitor
LABA + ICS
Malaria, uncomplicated (<5kg patients)
Malaria, uncomplicated
Asthma, pediatrics
ASO targeting Lp(a)
Secondary prevention of cardiovascular events in patients
with elevated levels of lipoprotein (a) (CVRR-Lp(a))
RTH258 BeovuⓇ
VEGF Inhibitor
Diabetic retinopathy
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
40View entire presentation